Glenmark Launches Travoprost Ophthalmic Solution for U.S. Market

Glenmark Pharmaceuticals has launched Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), a bioequivalent and therapeutically equivalent version of Travatan Z® Ophthalmic Solution USP, 0.004%, originally by Sandoz, Inc.

Details of Travoprost Ophthalmic Solution USP, 0.004%

According to IQVIA sales data for the 12 months ending September 2024, the market for Travatan Z® Ophthalmic Solution USP, 0.004% reported annual sales of approximately $66.2 million, highlighting the significant potential for Glenmark’s new offering. This launch marks Glenmark’s latest addition to its growing U.S. portfolio.

Current Glenmark US Portfolio

Currently, Glenmark’s U.S. portfolio includes 200 products authorized for distribution and 51 Abbreviated New Drug Applications (ANDAs) awaiting U.S. FDA approval. The company is also actively seeking external development partnerships to enhance and expand its product pipeline. This strategy aims to drive growth and solidify Glenmark’s presence in the competitive U.S. pharmaceutical market, particularly in the ophthalmic segment.

Commenting on the launch, Jim Brown, Senior Vice President, Sales and Marketing said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

On November 27, 2024, Glenmark Pharmaceuticals share price opened at ₹1,525.00, touching the day’s low at ₹1,507.55, as of 11:45 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.